Integra Lifesciences Holdings (IART) Change in Receivables (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Change in Receivables data on file, last reported at -$13.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables rose 36.39% year-over-year to -$13.6 million; the trailing twelve-month figure through Mar 2026 stood at $8.3 million (up 168.97% YoY), and the FY2025 full-year result was $485000.0, up 106.56% from the prior year.
• Change in Receivables slipped to -$13.6 million in Q1 2026, from $16.5 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $31.5 million in Q4 2024 to a low of -$28.8 million in Q3 2024.
• A 5-year average of $514941.2 and a median of $3.1 million in 2022 frame the typical range for Change in Receivables.
• Peak annual rise in Change in Receivables reached 6784.68% in 2024, while the deepest fall reached 12734.82% in 2024.
• Tracing IART's Change in Receivables over 5 years: stood at $10.0 million in 2022, then tumbled by 95.45% to $457000.0 in 2023, then soared by 6784.68% to $31.5 million in 2024, then sank by 47.71% to $16.5 million in 2025, then sank by 182.94% to -$13.6 million in 2026.
• Business Quant data shows IART's Change in Receivables at -$13.6 million in Q1 2026, $16.5 million in Q4 2025, and -$22.5 million in Q3 2025.